Abstract
Osteocalcin (OC) concentration, a specific index of bone formation, was measured in 29 female patients with microprolactinoma (serum prolactin, PRL: 105 ± 10.9 ng/ml; mean ± SE). Mean OC levels were significantly lower than in controls (1.7 ± 0.2 vs 5.1 ± 0.3 ng/ml; p < 0.001), being below the normal range in 28 out of 29 patients. All patients were treated with dopaminergic agents (dihydroergocriptine, bromocriptine or cabergoline). After treatment mean serum PRL levels were significantly reduced (12 ± 3.1 ng/ml; p < 0.001), a full normalization being obtained in 26 patients. There were no significant differences in both basal and after treatment PRL levels among patients treated with different drugs, although a greater PRL decrease was induced by cabergo-line. Serum OC levels significantly increased after 12 month therapy (4.7 ± 0.6 ng/ml, p < 0.001), a normal concentration being reached in 14 of 29 cases. During treatment there were no significant differences in serum estradiol and PRL concentrations between patients who normalized or not their OC levels, while the reduction in PRL levels with respect to baseline was more pronounced in the former group. The absolute increase in OC levels positively correlated with serum PRL decrements (p < 0.01). It is noteworthy that serum OC normalized in 1/10 patients during dihydroergocriptine, 3/8 during bromocriptine and 10/11 during cabergoline. Four patients, previously treated with dihydroergocriptine and bromocriptine without normalizing OC and PRL levels, underwent a second course of therapy with cabergoline and then normalized OC concentrations. In conclusion, these preliminary data show that i) OC levels are reduced in women with microprolactinoma, ii) after successful treatment of hyperprolactinemia a recovery of osteoblastic activity frequently occurs. Further investigations on the actions of dopaminergic drugs are needed, in view of their different effects on OC concentrations. Tresented in part at the 7th International Congress on calciotropic hormones and calcium metabolism, Salsomaggiore, Italy, October 1988.
References
Schlechte J.A., Sherman B., Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. J. Clin. Endocrinol. Metab. 56: 1120, 1983.
Koppelman M.C.S., Kurtz D.W., Morrish K.A., Bou E., Susser J.K., Shapiro J.R., Loriaux D.L. Vertebral body bone mineral content in hyperprolactinemic women. J. Clin. Endocrinol. Metab. 59: 1050, 1984.
Klibanski A., Biller B.M.K., Rosenthal D.I., Schoenfeld D.A., Saxe V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J. Clin. Endocrinol. Metab. 67: 124, 1988.
Caraceni M.P., Corghi E., Ortolani S., Casazza S., D’Alberton A., Motta T. Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia. Calcif. Tissue Int. 37: 687, 1985.
Klibanski A., Greenspan S.L. Increase in bone mass after treatment of hyperpro-lactinemic amenorrhea. N. Engl. J. Med. 315: 542, 1986.
Schlechte J., El-Khoury G., Kathol M., Walkner L Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J. Clin. Endocrinol. Metab. 64: 1021, 1987.
Price P.A., Parthemore J.G., Deftos L.J. New biochemical marker for bone metabolism. J. Clin. Invest. 66: 878, 1980.
Brown J.P., Delmas P.D., Malaval L, Edouard C, Chapuy M.C., Meunier P.J. Serum bone GLA-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1: 1091, 1984.
Lukert B.P., Higgins J.C., Stoskopf M.M. Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J. Clin. Endocrinol. Metab. 62: 1056, 1986.
Kruse K., Kracht U. Evaluation of serum osteocalcin as an index of altered bone metabolism. Eur. J. Pediatr. 145: 27, 1986.
Sartorio A., Ambrosi B., Colombo P., Morabito F., Faglia G. Osteocalcin levels in Cushing’s disease before and after treatment. Horm. Metabol. Res. 20: 70, 1988.
Fiore C.E., Clementi G., Prato A., Foti R., Conforto G. Bone mineral content of the hyperprolactinemic rat femur by single photon absorptiometry. Horm. Metabol. Res. 20: 40, 1988.
Rodin A., Duncan A., Quartero H.W.P., Pistofidis G., Mashiter G., Whitaker K., Crook D., Stevenson J.C., Chapman M.G., Fogelman I. Serum concentrations of alkaline phosphatase isoenzymes and osteocalcin in normal pregnancy. J. Clin. Endocrinol. Metab. 68: 1123, 1989.
Papapoulos S.E., Frolich M., Mudde A.H., Harinck I.J., Berg H., Bijvoet O.L.M. Serum osteocalcin in Paget’s disease of bone. J. Clin. Endocrinol. Metab. 65: 89, 1987.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sartorio, A., Conti, A., Ambrosi, B. et al. Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest 13, 419–422 (1990). https://doi.org/10.1007/BF03350694
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350694